Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DONIMI neoadjuvant domatinostat, nivolumab, and ipilimumab in stage III melanoma
NL-OMON54971Phase 1Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Domatinostat, nivolumab and ipilimumab in melanoma, cutaneous melanoma (CM) and melanoma of unknown primary (MUP) (4 arms), sponsored by Netherlands Cancer Institute. Primary endpoints: Safety and feasibility and Pathologic response rate. Started Jan 2020; status: completed.
02
Drugs
03
Conditions
melanomacutaneous melanoma (CM)melanoma of unknown primary (MUP)
Beyond the preview
Go deeper on NL-OMON54971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54971.